module 2- c- aripiprazole
TRANSCRIPT
Dopamine Activity in Healthy Individuals
Basal Activity
Maximal Activity
Normal Activity
Dopaminergic neurotransmission
log [drug]
Courtesy of Richard Mailman, modified from Mailman RB, Murthy V. Current pharmaceutical design 2010;16:488-501.
Schizophrenia: overactivity of the mesolimbic pathway
Basal Activity
Maximal Activity Schizophrenia
log [drug]
Courtesy of Richard Mailman, modified from Mailman RB, Murthy V. Current pharmaceutical design 2010;16:488-501.
Dopaminergic neurotransmission
Aripiprazole therapy
Basal Activity
Maximal Activity
Dotted sigmoidal line: actions of partial agonist in the presence of endogenous concentrations of dopamine.
Schizophrenia
log [drug]
Courtesy of Richard Mailman, modified from Mailman RB, Murthy V. Current pharmaceutical design 2010;16:488-501.
Dopaminergic neurotransmission
Dopamine Activity in Normal Circumstances
Basal Activity
Maximal Activity
Normal Activity
log [drug]Courtesy of Richard Mailman, modified from Mailman RB, Murthy V. Current pharmaceutical design 2010;16:488-501.
Dopaminergic neurotransmission
Dopamine System in Schizophrenia
Basal Activity
Maximal Activity
Normal Activity
Schizophrenia
log [drug]
Courtesy of Richard Mailman, modified from Mailman RB, Murthy V. Current pharmaceutical design 2010;16:488-501.
Aripiprazole Therapy
Basal Activity
Maximal Activity
Normal Activity
Schizophrenia
log [drug]Courtesy of Richard Mailman, modified from Mailman RB, Murthy V. Current pharmaceutical design 2010;16:488-501.
Dopaminergic neurotransmission
Aripiprazole effects on other dopamine pathways
Tuberoinfundibular Pathway Nigrostriatal Pathway
Less risk of hyperprolactinemia Less risk of EPS
Key Points• Aripiprazole is a partial agonist at D2 receptors.• It may act as an antipsychotic by:
– Lowering dopaminergic neurotransmission in the mesolimbic pathway.
– Enhancing dopaminergic activity in the mesocortical pathway.
• It has a lower risk of EPS and hyperprolactinemia than other antipsychotics